SOURCE-LINKED INTELLIGENCE

Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement

CORDIS · observation · Publication date unknown

ovative Health Initiative (IHI) of the European commission aiming at creating a collaborative ecosystem to accelerate the clinical validation of Next-Generation Sequencing (NGS)-based, multi-modality Artificial Intelligence (AI) oncology biomarkers and related technologies. By addressing technical and regulatory challenges, the consortium unites diverse expertise and resources to validate novel prostate and bladder cancer biomarkers, ensuring their efficacy and clinical utility. This initiative aligns with the goal of advancing precision medicine in oncology, ultimately improving patient outcomes and streamlining personalized cancer care. BRECISE's primary objective is to enhance biomarker-driven approaches for patient risk stratification, disease progression prediction, and treatment response assessment, within the framework of precision medicine. The project addresses the current challenge of limited access to clinically validated prognostic and predictive biomarkers in oncology. By providing healthcare professionals with NGS-based, multi-modality AI oncology biomarkers, BRECISE ai

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

13615935.25

unit

EUR